Equity Research Biotechnology

Should You Buy Zenas BioPharma, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Zenas BioPharma, Inc. (ZBIO) scores 5.0/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $31.93, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 0 CirclFi valuation models project upside for Zenas BioPharma, Inc. (ZBIO) at $31.93 — the models are evenly split, with a Quality Score of 5.0/10 and Value-Trap risk of 53/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 5.0/10 — Moderate — mixed signals
  • Value Trap Risk: 53/100 — Elevated — exercise caution
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

5.0 /10

Moderate — mixed signals

Value Trap Risk

53 /100
Elevated

Elevated — exercise caution

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for Zenas BioPharma, Inc. (ZBIO) in 2026?

What Is the Bull Case vs the Bear Case for Zenas BioPharma, Inc. (ZBIO)?

Bull case versus bear case for Zenas BioPharma, Inc. (ZBIO) at $31.93, derived from 0 active CirclFi valuation models on 2026-09-15.
Bull case Bear case
No active model projects meaningful upside for ZBIO at $31.93. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for ZBIO. The Value Trap score of 53/100 still argues for some caution.

How Does ZBIO Compare to Its Biotechnology Peers?

CVKD Cadrenal Therapeutic
5.1
ATYR aTyr Pharma, Inc.
5.0
LIPO Lipella Pharmaceutic
5.1
CADL Candel Therapeutics,
5.0
FULC Fulcrum Therapeutics
5.1
BLTE Belite Bio, Inc
5.0
BCDA BioCardia, Inc.
4.5
EPRX Eupraxia Pharmaceuti
2.4

Valuation data pages: CVKD · ATYR · LIPO · CADL · FULC · BLTE · BCDA · EPRX · INMB · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like ZBIO on Quality?

Closest companies to ZBIO’s Quality of Company score of 5.0/10, across all industries.

Which Biotechnology Screens Does ZBIO Appear In?

Why Do CirclFi’s 0 Models Disagree on ZBIO?

What Are the Biggest Risks of Buying ZBIO Stock?

Value Trap Warning

VT score 53/100 — apparent discount may mask decay.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ZBIO Data Page →

So Is Zenas BioPharma, Inc. (ZBIO) Worth Buying in 2026?

Zenas BioPharma, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. Zenas BioPharma, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ZBIO Stock?

Should I buy ZBIO stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for ZBIO at $31.93. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Zenas BioPharma, Inc.?

Key risks include: an elevated Value Trap score of 53/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does ZBIO compare to its competitors?

Among Biotechnology peers, ZBIO holds a Quality Score of 5.0/10. Comparable companies include CVKD (QOC 5.1), ATYR (QOC 5.0), LIPO (QOC 5.1). The relative ranking helps investors identify whether ZBIO offers better fundamental quality than alternatives in the same sector.

Is ZBIO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ZBIO's Quality Score of 5.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ZBIO at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ZBIO.

View ZBIO Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →